1.
Effects of Lactobacillus gasseri CP2305 on Mild Menopausal Symptoms in Middle-Aged Women.
Sawada, D, Sugawara, T, Hirota, T, Nakamura, Y
Nutrients. 2022;14(9)
-
-
-
Free full text
Plain language summary
The gastrointestinal tract represents the largest interface and interaction between the host and microorganisms. This collection of microorganisms is called the enteric or gut microbiota, and co-evolved with their hosts in an intricate, mutually beneficial relationship. One of the most important interactions is the brain–gut interaction, which maintains both intestinal homeostasis and brain function. The aim of this study was to analyse the influence of Lactobacillus gasseri CP2305 (CP2305) intake on the hypothalamic– pituitary–gonadal axis and its effects on mild symptoms associated with menopause. This study was a double-blind, placebo-controlled, parallel-group clinical trial. The enrolled subjects were randomly assigned to either the CP2305 group or placebo group. Results showed that consumption of CP2305 improves mild psychological symptoms that are unique to menopausal women, and improves the most common vasomotor symptoms, such as hot flashes. Authors concluded that the consumption of CP2305 may be used as an alternative treatment to alleviate menopausal symptoms.
Abstract
Lactobacillus gasseri CP2305 (CP2305) is a paraprobiotic that exhibits beneficial effects on the intestinal function and microbiota, and increases resistance to psychological stress. The stress response mechanism mainly involves the hypothalamic-pituitary-adrenal axis, which is influenced by the gut-brain axis. Furthermore, the gut-brain axis also communicates bidirectionally with the intestinal microbiota. Additionally, the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes share a common route that affects both mental and health aspects in women. This double-blind, placebo-controlled, parallel-group clinical trial aimed to analyze the influence of the intake of CP2305 on mild symptoms associated with menopause. Eighty women aged 40-60 years ingested CP2305 or placebo tablets for six consecutive menstrual cycles. Assessment was based on the observation of climacteric symptoms with two validated questionnaires-the Simplified Menopausal Index (SMI) and the Greene Climacteric Scale (GCS). The results showed that CP2305 provided significant relief in the SMI total score, SMI vasomotor score, SMI psychological score, GCS total score, GCS somatic score, and GCS vasomotor score compared to the placebo. The percentage of women with symptom relief for the SMI total score was 75.0%, with 30 of 40 women in the CP2305 group, and 55.0%, with 22 of 40 women in the placebo group (p = 0.0594). These findings provide new insights into the function of paraprobiotic CP2305 in relieving mild climacteric symptoms in women.
2.
Moderate Consumption of Beer (with and without Ethanol) and Menopausal Symptoms: Results from a Parallel Clinical Trial in Postmenopausal Women.
Trius-Soler, M, Marhuenda-Muñoz, M, Laveriano-Santos, EP, Martínez-Huélamo, M, Sasot, G, Storniolo, CE, Estruch, R, Lamuela-Raventós, RM, Tresserra-Rimbau, A
Nutrients. 2021;13(7)
-
-
-
Free full text
Plain language summary
During the menopause, hormonal changes can trigger uncomfortable symptoms such as hot flashes, night sweats, sleep disturbances, and vaginal dryness. Hormone replacement therapy does reduce some of the symptoms, however there has been an increased interest in alternative therapies such as phytoestrogens to relieve these symptoms. Phytoestrogens are compounds with oestrogen-like properties naturally found in plants. Beer is the main food source of the strongest phytoestrogen identified to date. The aim of this six-month parallel, controlled clinical intervention trial was to evaluate if a moderate daily intake of beer, with or without alcohol, could reduce menopausal symptoms in women. Female sex hormone profile and cardiovascular risk factors (CVRF) were also monitored. 34 postmenopausal women took part. One group included alcoholic beer (AB), and a second group added non-alcoholic beer (NAB) for 6 months. The control group took no alcohol in this time. After a 6-month follow-up both groups (AB and NAB) significantly reduced the severity of the menopause-related symptoms. These results must be considered as preliminary and will require confirmation with larger sample sizes.
Abstract
The menopausal transition can be a challenging period for women's health and a trigger of uncomfortable symptoms. Beer is the main food source of isoxanthohumol, a precursor of 8-prenylnaringenin, the strongest phytoestrogen identified to date. As phytoestrogens are reported to reduce perimenopausal symptoms, we evaluated if a daily moderate consumption of beer with (AB) and without alcohol (NAB) could improve menopausal symptoms and modify cardiovascular risk factors. A total of 37 postmenopausal women were enrolled in a parallel controlled intervention trial and assigned to three study groups: 16 were administered AB (330 mL/day), 7 NAB (660 mL/day), and 14 were in the control group. After a 6-month follow-up of the 34 participants who finished the trial, both interventions (AB and NAB) significantly reduced the severity of the menopause-related symptoms (p-value AB vs. Control: 0.009; p-value NAB vs. Control: 0.033). Moreover, AB had a beneficial net effect on psychological menopausal discomforts compared to the control group. As the sex hormone profile did not differ significantly between the study groups, the effects of both types of beers (AB and NAB) are attributed to the non-alcoholic fraction of beer. Furthermore, moderate NAB consumption improved the lipid profile and decreased blood pressure in postmenopausal women.